AMRI ups hydroxychloroquine sulfate API production

By The Science Advisory Board staff writers

May 1, 2020 -- AMRI Global will boost production of hydroxychloroquine sulfate active pharmaceutical ingredients (API) due to its potential effectiveness in treating COVID-19 symptoms in patients.

AMRI's active type II drug master file for hydroxychloroquine sulfate, which was issued an emergency use authorization by the U.S. Food and Drug Administration to treat some hospitalized patients with COVID-19, is available to support increased need.

The company remains committed to working with drug product producers, government agencies, and associated health authorities globally to ensure access to this API as demand increases.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.